Inflammation in Hypertension: Current Therapeutic Approaches

Androulakis, Emmanuel; Tousoulis, Dimitris; Papageorgiou, Nikolaos S.; Latsios, George; Siasos, Gerasimos; Tsioufis, Costas; Giolis, Anastasios; Stefanadis, Christodoulos

doi:10.2174/138161211798764753

Cited by 30 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A close relation between hypertension and inflammation is reported by investigators [26,27]. Pathophysiologically, inflammation has been implicated in both endothelial dysfunction and arterial stiffness in hypertension and it is assumed that every mechanism leading to inflammation will accelerate this process [27].…”

Section: Discussionmentioning

confidence: 78%

Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes

Alatab

Fakhrzadeh

Sharifi

et al. 2014

J Diabetes Metab Disord

View full text Add to dashboard Cite

BackgroundPresence of Diabetes Mellitus increases the risk of subclinical atherosclerosis. In this study was aimed to determine the influence of hypertension (HTN) on surrogate markers of atherosclerosis in a population of patients with early type 2 diabetes.Methods125 diabetic subjects drawn from Dr. Shariati outpatient’s clinic list and 153 non- diabetic subjects who were the relatives in law of diabetic participants were recruited. Participants with type 2 diabetes were free of clinical evidence of cardiovascular disease and renal involvement. Two groups of diabetic and control were further divided into two subgroups of hypertensive (known case of HTN or blood pressure ≥140/90 mmHg) and normotensive, and anthropometric characteristics, metabolic biomarkers as well as markers of subclinical atherosclerosis including Carotid intima media thickness (CIMT), flow mediated dilation (FMD) and Ankle Brachial Index (ABI) were measured.ResultsDiabetic group with a mean age of 49.9 ± 7.5 years had significantly higher CIMT (0.64 ± 0.14 vs 0.76 ± 0.19, p = 0.001) and lower FMD (16.5 ± 8.1 vs 13.3 ± 7.1, p = 0.003) and ABI (1.2 ± 0.1 vs 1.1 ± 0.1, p = 0.01) than control with mean age of 52.9 ± 10.1 years. 34% of control and 59.2% of diabetic were hypertensive. Fasting blood sugar, insulin levels and calculated insulin resistance index of HOMA IR. of hypertensive subjects were higher than normotensive subjects in both groups of diabetic and non-diabetic. Similar pattern was presented for measured inflammatory mediators of hs-CRP and IL-6. Among subclinical atherosclerosis markers, only CIMT was significantly different between hypertensive and normotensive subjects in both groups. In adjusted linear regression analysis, a constant significant association existed between age and CIMT, ABI and FMD in non-diabetic, while in diabetic, age only correlated with CIMT and not the other two markers. In multiple regression model, HTN was recognized as a risk factor for increasing CIMT (OR = 2.93, 95% CI = 1.03-8.33, p = 0.04) but not attenuating FMD or ABI.ConclusionsSince FMD and CIMT may measure a different stage of subclinical atherosclerosis in diabetic patients, influence of HTN on these markers might be different.

show abstract

Section: Discussionmentioning

confidence: 78%

Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes

Alatab

Fakhrzadeh

Sharifi

et al. 2014

J Diabetes Metab Disord

View full text Add to dashboard Cite

show abstract

“…ANG is involved in renal pathology including inflammation, oxidative stress, and tissue fibrosis [14]. Inflammation is characterized by hypertension-induced target organ damage [1]. In the present study, we did not examine the recruitment of immune cells to target organs.…”

Section: Discussionmentioning

confidence: 87%

Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes

Choi

Ryu

Kee

et al. 2015

Vascular Pharmacology

View full text Add to dashboard Cite

“…The role of hypertension as a crucial underlying process contributing to the initiation and the progression of atherosclerosis as well as its clinical manifestations is well established [33]. Recent reports have also shown a strong association between hypertension and the inflammatory process [34]. Furthermore, a patient's resting heart rate is a well-recognized marker of autonomic nervous system tone and, in many clinical investigations, has been found to correlate with cardiovascular morbidity and mortality [35,36].…”

Section: Discussionmentioning

confidence: 99%

Elevated Plasma Level of Pentraxin-3 Predicts In-Hospital and 30-Day Clinical Outcomes in Patients with Non-ST-Segment Elevation Myocardial Infarction Who Have Undergone Percutaneous Coronary Intervention

Guo

Wen

et al. 2014

Cardiology

View full text Add to dashboard Cite

Objectives: This investigation explored the short-term prognostic value of pentraxin-3 (PTX3) levels in patients with non-ST-segment elevation myocardial infarction (NSTEMI) treated by percutaneous coronary intervention (PCI). Methods: We measured plasma levels of PTX3 and other biomarkers in 525 PCI-treated NSTEMI patients (mean age, 57.7 years; 328 males). The associations of PTX3 levels with cardiac events and cardiac deaths occurring within 30 days of discharge were evaluated with multivariable Cox proportional hazard models. Results: Renal function, diabetes prevalence, systolic blood pressure, heart rate and ejection fraction differed significantly in the high PTX3 (≥3.0 ng/ml, n = 107) and low PTX3 (<3.0 ng/ml, n = 418) groups (all p < 0.05). Plasma PTX3 levels were correlated with high-sensitivity C-reactive protein, troponin T and N-terminal pro-B-type natriuretic peptide in NSTEMI patients (all p < 0.05). Kaplan-Meier analysis showed in-hospital and 30-day cardiac events and deaths were higher in the high PTX3 group (both p < 0.01). Elevated PTX3 was an independent predictor of 30-day cardiac events (95% CI 1.09-1.68; p = 0.006) and mortality (95% CI 1.18-2.15; p = 0.002). Conclusions: An elevated plasma level of PTX3 predicts 30-day cardiac events and mortality in PCI-treated NSTEMI patients.

show abstract

Inflammation in Hypertension: Current Therapeutic Approaches

Cited by 30 publications

References 0 publications

Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes

Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes

Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes

Elevated Plasma Level of Pentraxin-3 Predicts In-Hospital and 30-Day Clinical Outcomes in Patients with Non-ST-Segment Elevation Myocardial Infarction Who Have Undergone Percutaneous Coronary Intervention

Contact Info

Product

Resources

About